Hepatocellular Carcinoma - Opportune indication for novel therapies

Questions: Discounts, Updates etc.

Price: $3,800.00

Publication Date: 2007-06-15

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The close association with hepatitis means that hepatocellular carcinoma (HCC) is common in developing countries where hepatitis B and C infections are endemic. However, the increasing prevalence of hepatitis in the West means that incidence of HCC in the US and Europe is expected to increase significantly over the coming years.


Scope

  • Overview of hepatocellular carcinoma, including epidemiology, staging, prognosis and unmet needs
  • Review of current treatment modalities and physician opinion of existing and future treatment strategies
  • Evaluation of key drugs currently used in the treatment of hepatocellular carcinoma
  • Review of late-phase drugs in development for hepatocellular carcinoma including key opinion leaders' view on their potential


    • Report Highlights
    Typically a disease of the developing countries, incidence of HCC is increasing in the West due to increasing cases of hepatitis infection, thus representing a revenue opportunity for pharmaceutical and biotechnology companies with targeted therapies.

    HCC patients are poorly served by existing treatment options, with only a small proportion amenable to curative therapy such as surgical resection and liver transplantation. Prognosis is poor for unresectable patients, and there remains no standard drug therapy for advanced HCC.

    Given the lack of standard of care, R&D interest in HCC is relatively high, with 37 compounds in clinical development. The majority consist of targeted therapies, with Bayer-Schering/Onyx's Nexavar, Genentech/Roche's Avastin and OSI/Genentech/Roche's Tarceva considered to have the highest clinical and commercial potential.


    Reasons to Purchase

  • Evaluate opportunities and risks in the HCC market by analyzing the clinical and commercial potential of key pipeline drugs
  • Review critical factors that drive the HCC market to assess the potential of existing and pipeline drugs for the disease
  • Understand current and future competitive dynamics of HCC to determine the attractiveness of the market

    • Table of Contents

    Other users found this report page using the following search terms: hcc hepatocellular cancer liver amt2003 hepatocellular carcinoma hcc cancer liver auron nexavar classification treatment

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.